IL-12-based therapy of malignancies

Drugs of Today

Volumn 37, Issue 9, 2001, Pages 629-637

  Li, S ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CELL ACTIVATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ELECTROPORATION; GENE EXPRESSION SYSTEM; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL;

EID: 0035204598     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.9.844222     Document Type: Review

References (94)

1. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes
2. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes
3. Cytokines (IFNs, TNF-α IL-2 and IL-12) and animal models of cancer
4. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies
5. Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12
6. Exogenous expression of mouse interferon-γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity
7. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk
8. Cytokine-induced tumor immunogenicity: From exogenous cytokines to gene therapy
9. IFN-γ induces IL-12 mRNA expression by a murine macrophage cell line, J774
10. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
11. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
12. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
13. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
14. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma
15. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer
16. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses
17. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri)
18. IL-12 deaths: Explanation and a puzzle
19. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen
20. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model
21. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoralimmunity
22. Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at a distant site
23. Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: Implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy
24. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines
25. Cancer immunotherapy of established tumors with IL- 12. Effective delivery by genetically engineered fibroblasts
26. Amount of interleukin 12 available at the tumor site is critical for tumor regression
27. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo
28. Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy
29. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector
30. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer
31. Gene therapy of cancer: A pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response
32. Construction and characterization of retroviral vectors for interleukin-2 gene therapy
33. Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin12 (IL-12)
34. Combination gene therapy of IL-12 and allogeneic MHC class I gene via stimulating NK cytolytic activity
35. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats
36. Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells
37. Efficient cotransduction of tumors by multiple herpes simplex vectors: Implications for tumor vaccine production
38. Interleukin-12 (IL-12) gene therapy of leukemia: Immune and antileukemic effects of IL-12-transduced hematopoietic progenitor cells
39. Antitumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells
40. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases
41. Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL 12) subunits in a rat medullary thyroid carcinoma model
42. Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model
43. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma
44. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12
45. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer
46. Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12
47. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12
48. Gene therapy for cancer: What have we done and where are we going?
49. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma
50. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors
51. Intravenous cytokine gene delivery by lipid-DNA complex controls the growth of established lung metastases
52. Direct transfer of IL-12 gene into growing RENCA tumors
53. Viral vector delivery in solid-state vehicles: Gene expression in a murine prostate cancer model
54. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model
55. Prostate cancer gene therapy: Comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines
56. B7.1 expression eliminates tumor resistance to IL-12 gene therapy
57. Combination of interleukin 12 and interferon-α gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma
58. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy
59. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: Long-term remission of liver metastases in a mouse model
60. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine
61. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: Cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization
62. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major
63. Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12
64. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer
65. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: Critical role of natural killer cell interferon-γ production and Stat-mediated signal transduction
66. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study
67. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study
68. Cytokine gene therapy of cancer using interleukin-12: Murine and clinical trials
69. Regulation of human cytolytic lymphocyte responses by interleukin-12
70. Natural killer (NK) cell stimulatory factor or IL12 has differential effects on the proliferation of TCR-α β+, TCR-γ δ+ T lymphocytes, and NK cells
71. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells
72. Interleukin-12: A cytokine at the interface of inflammation and immunity
73. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography
74. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
75. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity
76. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice
77. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level
78. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes
79. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases
80. Recruitment of Stat4 to the human interferon-α/β receptor requires activated Stat2
81. Characterization of cytokine differential induction of Stat complexes in primary human T and NK cells
82. Interferon-α activates multiple Stat proteins and upregulates proliferation-associated IL-2R-α, c-myc, and pim-1 genes in human T cells
83. T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases
84. Impairment of Stat activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections
85. p38 MAP kinase is required for Stat1 serine phosphorylation and transcriptional activation induced by interferons
86. Stat1 α expression is involved in IFN-γ induction of the class II transactivator and class II MHC genes
87. Regulation of Stat1 nuclear export by Jak1
88. The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction
89. Jak-Stat pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
90. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo
91. Synergy between interferon-γ and tumor necrosis factor-α in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor κB
92. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo
93. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
94. IFN-γinducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy